Abbott boosted by strong Q4 medtech sales
This article was originally published in Clinica
Executive Summary
Abbott’s medtech division ended 2009 on a high after it recorded significant gains in Q4 revenues. Despite weak sales in the US for most of its medtech segments except molecular diagnostics, the group’s overall medical products business managed to show growth through strength in the international markets and favourable currency exchange rates.